TradingKey

More Details of CorMedix Inc Company

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Company Info

Ticker SymbolCRMD

Company nameCorMedix Inc

IPO dateMar 25, 2010

CEOMr. Joseph Todisco

Number of employees64

Security typeOrdinary Share

Fiscal year-endMar 25

Address300 Connell Drive

CityBERKELEY HEIGHTS

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code07922

Phone19085179500

Websitehttps://cormedix.com/

Ticker SymbolCRMD

IPO dateMar 25, 2010

CEOMr. Joseph Todisco

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Joseph Todisco

Chief Executive Officer, Director

323.43K

-2.01%

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

Dr. Alan William Dunton, M.D.

Independent Director

--

Ms. Elizabeth (Liz) Massonhurlburt

Executive Vice President, Chief Clinical Strategy and Operations Officer

--

Dr. Matthew T. (Matt) David, M.D.

Chief Financial Officer, Executive Vice President

--

Ms. Beth Zelnick Kaufman

Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary

--

Name

Name/Position

Position

Shareholding

Change

Mr. Joseph Todisco

Chief Executive Officer, Director

323.43K

-2.01%

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

Revenue Breakdown

FY2025Q1

FY2024

No Data

By RegionUSD

Name

Revenue

Proportion

United States

39.08M

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

6.42%

Abdalkader (Shaibatalhamd Aymen)

6.22%

The Vanguard Group, Inc.

5.77%

Marshall Wace LLP

3.46%

Citadel Advisors LLC

2.30%

Other

75.83%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

6.42%

Abdalkader (Shaibatalhamd Aymen)

6.22%

The Vanguard Group, Inc.

5.77%

Marshall Wace LLP

3.46%

Citadel Advisors LLC

2.30%

Other

75.83%

Shareholder Types

Shareholders

Proportion

Investment Advisor

22.34%

Investment Advisor/Hedge Fund

13.04%

Hedge Fund

8.73%

Individual Investor

7.30%

Research Firm

1.48%

Sovereign Wealth Fund

1.26%

Pension Fund

0.63%

Bank and Trust

0.28%

Venture Capital

0.06%

Other

44.87%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

280

26.40M

35.51%

-7.69M

2025Q1

281

29.73M

44.27%

-179.25K

2024Q4

252

24.74M

40.82%

-30.08K

2024Q3

228

19.79M

34.25%

-1.78M

2024Q2

217

17.74M

32.28%

-4.09M

2024Q1

218

17.92M

32.60%

-5.73M

2023Q4

217

19.38M

35.35%

-2.82M

2023Q3

208

18.46M

33.68%

-3.54M

2023Q2

197

19.74M

38.10%

+6.18M

2023Q1

190

11.28M

25.34%

-2.76M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

4.31M

5.8%

+109.81K

+2.61%

Mar 31, 2025

The Vanguard Group, Inc.

3.63M

4.89%

+255.97K

+7.58%

Mar 31, 2025

Marshall Wace LLP

230.53K

0.31%

+230.53K

--

Mar 31, 2025

State Street Global Advisors (US)

1.54M

2.07%

+85.97K

+5.92%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.43M

1.93%

+40.10K

+2.88%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

940.59K

1.27%

+940.59K

--

Dec 31, 2024

Related ETFs

Updated: Wed, Aug 6

Name

Proportion

Invesco Dorsey Wright Healthcare Momentum ETF

1.62%

SPDR S&P Pharmaceuticals ETF

1.31%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.81%

First Trust Active Factor Small Cap ETF

0.41%

Vanguard US Momentum Factor ETF

0.21%

iShares Micro-Cap ETF

0.18%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.09%

ProShares Ultra Nasdaq Biotechnology

0.09%

iShares Biotechnology ETF

0.08%

Invesco Nasdaq Biotechnology ETF

0.08%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion1.62%

SPDR S&P Pharmaceuticals ETF

Proportion1.31%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion0.81%

First Trust Active Factor Small Cap ETF

Proportion0.41%

Vanguard US Momentum Factor ETF

Proportion0.21%

iShares Micro-Cap ETF

Proportion0.18%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proportion0.09%

ProShares Ultra Nasdaq Biotechnology

Proportion0.09%

iShares Biotechnology ETF

Proportion0.08%

Invesco Nasdaq Biotechnology ETF

Proportion0.08%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

CorMedix Inc

14.350USD

CorMedix Inc

14.350

Overview

Company

Financials

Analysis